Enliven Therapeutics, Inc. / Fundamentals
Income statement
- Net revenue
€0.00 - Cost of goods sold
€138.14K - Gross profit
-€69.50K - SG&A expenses
€22.20M - R&D expenses
€75.82M - EBITDA
-€97.88M - D&A
€206.78K - EBIT
-€98.02M - Interest expenses
€0.00 - EBT
-€86.38M - Tax expenses
-€429.00K - Net income
-€85.98M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€1.55M - Changes in working capital
€4.17M - Operating cash flow
-€60.56M - Capex
€155.30K - Other investing cash flow
€730.16K - Net investing cash flow
-€187.18M - Total cash dividends paid
€0.00 - Issuance of common stock
€220.99M - Debt repayment
€0.00 - Other financing cash flow
€78.79M - Net financing cash flow
€222.82M - Foreign exchange effects
€0.00 - Net change in cash
€19.32M - Cash at end of period
€102.48M - Free cash flow
-€60.40M
Balance sheet
- Cash and cash equivalents
€102.48M - Cash and short-term investments
€420.85M - Total receivables
€0.00 - Inventory
€0.00 - Other current assets
€4.39M - Total current assets
€425.24M - Property, plant & equipment
€880.31K - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€6.21M - Total non-current assets
€7.09M - Total assets
€432.34M - Accounts payable
€2.02M - Short-term debt
€322.61K - Other current liabilities
€10.71M - Total current liabilities
€13.05M - Long-term debt
€0.00 - Deferred tax liabilities
€0.00 - Other non-current liabilities
€175.03K - Total non-current liabilities
€175.03K - Total liabilities
€13.23M - Common stock
€50.62K - Retained earnings
-€255.13M - Other equity
-€151.87K - Total equity
€419.11M - Total liabilities and shareholders' equity
€432.34M
Company information
- Market capitalization
€1.01B - Employees
62 - Enterprise Value
€860.30M
Company ratios
- Gross margin
-
0.0% - EBITDA margin
-
0.0% - EBIT margin
-
0.0% - EBT margin
-
0.0% - Net margin
-
0.0% - ROE
-
-20.5% Much worse than peer group: 145.2% - ROA
-
-19.9% Much better than peer group: -10,007.0% - Asset turnover
-
0.0% - FCF margin
-
0.0% - FCF yield
-6.0% - Efficiency ratio
0.0% - Net sales per employee
-
€0.00 - Net income per employee
-
-€1.39M